Rignotec raises €15 million to advance RIG-I targeted immuno-oncology therapeutics
6 September 2016 | By Niamh Louise Marriott, Digital Content Producer
The funding will advance the ongoing development of Rigontec’s RIG-I agonist platform targeting oncological, anti-infective and inflammatory indications as well as accelerate the progress of lead candidate RGT100 towards the clinic...